Sirtuins, NAD⁺, and the Quiet Biology Framework

QUIET BIOLOGY FRAMEWORK | Scientific Support Document

Finley Proudfoot | Quiet Biology Framework | March 2026

Abstract

The Quiet Biology series has established phosphorylation, the addition and removal of phosphate groups from proteins, as the cell’s primary control language, with AKT-driven MDM2 phosphorylation as the convergence point through which chronic metabolic dysregulation simultaneously suppresses p53 and dysregulates AR turnover. This paper introduces a second, parallel control system that operates alongside phosphorylation and interacts with many of the same proteins: acetylation and deacetylation, regulated by a family of enzymes called sirtuins.

Sirtuins are NAD⁺-dependent enzymes, their activity is directly tied to the cell’s metabolic state. When the cell is in energy deficit, during fasting, caloric restriction, or exercise, NAD⁺ levels rise, sirtuin activity increases, and a range of cellular maintenance and quality-control processes are activated. When the cell is in chronic metabolic excess, NAD⁺ availability falls, sirtuin activity declines, and these protective processes are progressively withdrawn.

This paper examines how the sirtuin system, and specifically SIRT1, interacts with p53, MDM2, and the androgen receptor, the same proteins that have been central to the MDM2 Convergence and Rapamycin papers. The interactions are direct, well-evidenced, and clinically relevant. SIRT1 deacetylates p53, modifying its stability and activity.^[1]

SIRT1 directly deacetylates and suppresses the androgen receptor, reducing its transcriptional output and inhibiting prostate cancer cell growth.^[2]

And the SIRT1, AMPK, mTOR axis represents one of the primary molecular pathways through which caloric restriction, exercise, and metabolic health influence longevity.^[3]

The quiet biology protocol already supports the sirtuin system, without explicitly targeting it, through every one of its core elements. Understanding why is the subject of this paper.

This paper is the companion to the MDM2 Convergence paper. Where that paper describes the phosphorylation-based regulatory failure, AKT driving MDM2 into the nucleus, simultaneously suppressing p53 and dysregulating AR turnover, this paper describes the parallel acetylation-based failure operating on the same proteins through the same upstream metabolic cause. The two papers are designed to be read together. The MDM2 Convergence paper closes with an introduction to the acetylation axis; this paper provides its full account.

01What Sirtuins Are, A Plain Introduction

Sirtuins are a family of seven proteins (SIRT1 through SIRT7 in humans) that act as cellular maintenance managers. Their job is to remove acetyl groups from other proteins, a chemical modification that, depending on the protein, can switch it on, switch it off, change where it goes inside the cell, or alter how long it survives before being broken down.

They are sometimes called ’longevity proteins’ because the yeast version of the family, Sir2, was one of the first proteins shown to extend lifespan when its activity was increased, and reducing its activity shortened lifespan. The mammalian sirtuins, particularly SIRT1, have been linked to the beneficial effects of caloric restriction across multiple species, the observation that eating less while maintaining adequate nutrition extends healthy lifespan in virtually every organism it has been tested in.

The critical feature of sirtuins that connects them to the quiet biology framework is their dependence on NAD⁺. NAD⁺ (nicotinamide adenine dinucleotide) is a molecule produced during cellular energy metabolism. Its levels rise when the cell is in a low-energy, maintenance-oriented state, during fasting, exercise, or caloric restriction. They fall when the cell is in a state of chronic metabolic excess. This means that sirtuin activity is directly tied to metabolic conditions: sirtuins are more active when the cell most needs their maintenance and quality-control functions, and less active when chronic excess has undermined the very conditions that support them.^[4]

02SIRT1 and p53, A Complex Relationship

The relationship between SIRT1 and p53 is one of the best-studied interactions in the sirtuin field, and it is also one of the most nuanced. Understanding it requires keeping in mind that SIRT1’s effects are context-dependent, the same action can produce different biological outcomes depending on the cellular state and the broader signalling environment.

How SIRT1 regulates p53

SIRT1 deacetylates p53 at specific sites on the protein, most importantly at lysine 382. Acetylation at this site stabilises p53 and enhances its ability to activate the genes that carry out its quality-control functions, including cell cycle arrest and DNA repair. When SIRT1 removes this acetyl group, p53 becomes less stable and more accessible to MDM2-mediated breakdown.^[1]

Importantly, the same acetylation that SIRT1 removes is also what blocks MDM2 from binding to p53 and marking it for destruction. When p53 is acetylated, MDM2 cannot easily access the binding sites it needs. When SIRT1 deacetylates p53, it effectively hands it back to MDM2 for disposal. SIRT1 and MDM2 are therefore not independent systems, they are cooperating mechanisms in the same process of keeping p53 in check under normal, non-stressed conditions.^[5]

Why this is not simply harmful

In healthy biology, p53 is not supposed to be continuously active. It is designed to pulse, to rise in response to genuine cellular stress, do its quality-control work, and then return to a resting state. SIRT1-mediated deacetylation of p53 is part of the normal mechanism by which p53 is returned to its resting state after each activation cycle. Without this reset, p53 would remain chronically active, which causes its own problems, including excessive cell death, accelerated ageing of stem cell populations, and tissue deterioration. Under conditions of metabolic health, where NAD⁺ is abundant and SIRT1 is active, the system works as designed: p53 pulses appropriately, SIRT1 helps reset it, and the oscillatory quality-control cycle runs properly.^[4]

Under conditions of chronic metabolic excess, where NAD⁺ is depleted and SIRT1 activity falls, this reset mechanism degrades. But the primary p53-suppressive force in that environment is not absent SIRT1, it is elevated MDM2, driven by chronic AKT activation, as established in the MDM2 Convergence paper. The sirtuin story and the MDM2 story are parallel, not the same.

The contextual nature of SIRT1’s role in cancer

The relationship between SIRT1 and cancer is genuinely complex, and the research reflects this. In some cancer models, SIRT1 appears tumour-promoting because its p53 suppression allows cells to survive stress that would otherwise trigger p53-mediated death. In other models, including prostate cancer, SIRT1 appears tumour-suppressive through its direct action on the androgen receptor, which is examined in the next section.^[6]

03SIRT1 and the Androgen Receptor, A Tumour-Suppressive Role

In prostate cancer biology, the most clinically significant sirtuin interaction is not with p53 but with the androgen receptor. And here the story is considerably cleaner: SIRT1 acts as a direct suppressor of androgen receptor activity in prostate tissue, and its loss, or its displacement from the nucleus to the cytoplasm, makes prostate cells more sensitive to androgen stimulation and harder to treat with hormone-blocking therapies.

How SIRT1 restrains the androgen receptor

SIRT1 binds directly to the androgen receptor and deacetylates it at a conserved set of lysine residues in the receptor’s hinge region. This deacetylation reduces the AR’s transcriptional activity, specifically its ability to drive the expression of growth-promoting genes in response to testosterone and DHT. Laboratory studies have shown that SIRT1 expression in AR-positive prostate cancer cells directly inhibits their growth in response to androgen stimulation, and that blocking SIRT1 activity markedly increases the sensitivity of those cells to androgens.^[2]

This has a direct implication for hormone therapy. Androgen-blocking drugs, the standard approach to advanced prostate cancer, work in part by recruiting SIRT1 to androgen receptor-responsive gene promoters, where it deacetylates local histone proteins and switches those genes off. When SIRT1 is depleted or its activity is reduced, this suppressive mechanism fails, and the androgen-blocking drugs lose some of their effectiveness. SIRT1 is not just a background player in prostate cancer biology. It is part of the mechanism through which androgen suppression achieves its therapeutic effect.^[7]

The TRT connection

The TRT and MDM2 papers in this series have argued that testosterone’s effect on the AR is context-dependent, that the risk is not primarily in the hormone but in the regulatory state of the AR system. The SIRT1 story adds another dimension to this argument. In a man whose SIRT1 is active and whose NAD⁺ levels are adequate, conditions supported by the metabolic health that the quiet biology protocol aims to establish, SIRT1 is continuously providing a direct restraining influence on the AR. Androgen stimulation via TRT enters a system in which an endogenous suppressive mechanism is operational.^[8]

In a man whose SIRT1 activity is compromised by metabolic excess, chronic inflammation, or NAD⁺ depletion, that restraining influence is weakened or absent. The same testosterone dose activates an AR system that has lost one of its natural brakes. This is a further metabolic context argument for why TRT decisions cannot be made on the basis of testosterone level alone, and why improving the underlying metabolic environment directly affects the regulatory state of the AR system into which testosterone is being delivered.

04The SIRT1, AMPK, mTOR Axis, The Longevity Connection

The most important thing to understand about sirtuins in the context of the quiet biology framework is not any single interaction but the place they occupy in the broader metabolic signalling network. SIRT1, AMPK, and mTOR are not three independent systems. They are interconnected nodes in the same network, and they move together in response to metabolic conditions.

When metabolic conditions favour maintenance, during fasting, caloric restriction, or exercise, NAD⁺ rises, activating SIRT1. AMP levels also rise, activating AMPK. SIRT1 and AMPK reinforce each other: AMPK activation promotes NAD⁺ production, further increasing SIRT1 activity, while SIRT1 deacetylates and activates AMPK. Both then act on mTOR: AMPK inhibits mTORC1 directly, and SIRT1 inhibits mTOR through deacetylation of components of the mTOR complex.^[3]

The result is a coordinated shift toward cellular maintenance, mTOR quietens, autophagy runs, mitochondrial biogenesis is activated through SIRT1’s deacetylation of PGC-1α, and the cell enters a state of quality-focused rather than growth-focused activity.^[4]

When metabolic conditions favour growth, during chronic nutrient excess, elevated insulin, or persistent mTOR activation, this network shifts in the opposite direction. NAD⁺ availability declines, reducing SIRT1 activity. AMPK is suppressed by the elevated AMP:ATP ratio of an energy-replete cell. mTOR is chronically active. The maintenance-oriented programme is progressively withdrawn, and the cell locks into the growth-dominant state that the preceding papers have described as the permissive condition for both cancer and accelerated ageing.

05The Protocol Already Supports the Sirtuin System

One of the most practically important observations in this paper is that the quiet biology protocol, designed around mTOR oscillation and metabolic constraint, is already a sirtuin-activating protocol, not by explicit design, but as a consequence of the same metabolic mechanisms that govern both systems.

Cyclic mTOR suppression via rapamycin

During the rapamycin suppression phase, mTOR activity falls. This reduces the metabolic drain on NAD⁺ that chronic mTOR activation imposes, because mTOR-driven anabolic processes are energetically expensive and consume metabolic resources including NAD⁺ precursors. As mTOR quietens, the metabolic conditions that support sirtuin activity improve. SIRT1’s restraining effects on both p53 and the AR are enhanced during the suppression window.

Exercise

Exercise is the most potent physiological activator of the SIRT1, AMPK axis. During exercise, both NAD⁺ levels and AMP levels rise, activating both SIRT1 and AMPK simultaneously. The exercise window in the protocol is therefore not simply a period of metabolic stress and AMPK activation, it is also a period of direct sirtuin activation, during which SIRT1’s suppressive effect on the AR and its quality-control interactions with p53 are at their strongest.^[3]

Metabolic constraint

Reducing chronic insulin signalling and improving insulin sensitivity directly improves NAD⁺ metabolism by reducing the mTOR-dependent metabolic load on NAD⁺ production. Studies of caloric restriction have consistently shown that its longevity effects are associated with increased SIRT1 activity through this NAD⁺ mechanism. The metabolic constraint element of the protocol is, in mechanistic terms, a partial pharmacological caloric restriction, achieving some of the same metabolic shifts through dietary timing, retatrutide, and reduced nutrient excess.^[4]

Mitophagy and mitochondrial quality

SIRT3, the mitochondrial member of the sirtuin family, plays a specific role in regulating mitochondrial ROS production and protecting mitochondrial quality. Improved mitochondrial health, the goal of the Urolithin A phase in the protocol, supports SIRT3 function. Healthier mitochondria produce more NAD⁺, which feeds back to support SIRT1 activity across the cell. Mitophagy and sirtuin activation are therefore mutually reinforcing: healthier mitochondria support sirtuin function, and active sirtuins promote the conditions in which mitophagy can run effectively.^[9]

06NMN, NR, and Sirtuin Supplementation, Where They Fit

There is considerable clinical and popular interest in NAD⁺ precursor supplements, particularly NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), as tools for raising NAD⁺ levels and thereby activating sirtuins. Given the connections described in this paper, this interest is scientifically grounded. The question is not whether these supplements have relevant biological effects, but whether they add meaningfully to what the protocol already achieves.

For a man whose metabolic environment is substantially improved by the protocol, who is exercising regularly, managing insulin sensitivity, cycling rapamycin, and supporting mitochondrial quality, the additional NAD⁺ benefit from supplementation may be modest. The primary driver of NAD⁺ depletion is the chronic metabolic excess that the protocol addresses upstream. Supplementing NAD⁺ precursors without addressing that upstream cause is adding substrate to a system that is still running in the wrong direction.

For a man in the earlier stages of the protocol, or one whose metabolic compromise is substantial, NMN or NR supplementation may provide a useful additional support to the sirtuin axis while the metabolic foundations are being established. It is not a substitute for the protocol’s core elements, but it is not a distraction from them either, provided the downstream goal is understood as the improvement of metabolic conditions rather than the supplementation of a single molecule in isolation.

07Acetylation as a Second Control Layer

The Rapamycin paper in this series established that phosphorylation is the primary control language of the cell, the mechanism through which signals are turned on, turned off, relocated, and timed. Acetylation, regulated by sirtuins and their counterpart enzymes (the histone acetyltransferases that add acetyl groups), is a second, parallel control language that operates on many of the same proteins.

p53 is regulated by both phosphorylation and acetylation. Its activation in response to DNA damage requires phosphorylation events that stabilise it and block MDM2 binding, and acetylation events that enhance its transcriptional activity. Its deactivation after a stress cycle requires MDM2-mediated ubiquitination, which is facilitated by SIRT1-mediated deacetylation. The two systems cooperate to produce the oscillatory behaviour that is essential to p53’s biological function.^[1][5]

The androgen receptor is similarly regulated by both phosphorylation and acetylation. Its acetylation by p300 and related enzymes enhances its transcriptional activity and promotes the co-activator interactions that drive growth-promoting gene expression. Its deacetylation by SIRT1 reverses this, reducing its transcriptional output and its sensitivity to androgens. The AR stability story described in the TRT and MDM2 papers is largely a phosphorylation story, MDM2-mediated ubiquitination driven by AKT phosphorylation. The SIRT1 story is an acetylation story. Both are operating simultaneously on the same protein, in the same direction, with overlapping effects.^[8]

This convergence is precisely what makes the quiet biology framework coherent at a systems level. It is not a collection of individual interventions on individual proteins. It is a set of metabolic conditions that simultaneously influence both control languages, phosphorylation and acetylation, in the direction of quality, rhythm, and constraint rather than growth, persistence, and dysregulation.

Conclusion

Sirtuins are not a separate topic from the rest of the quiet biology framework. They are part of the same underlying story, told through a different molecular mechanism. SIRT1’s deacetylation of p53 is part of the normal oscillatory reset that returns p53 to its resting state after stress activation. SIRT1’s deacetylation of the androgen receptor is a direct, endogenous brake on AR-driven transcription in prostate tissue. And the SIRT1, AMPK, mTOR network is one of the primary molecular pathways through which metabolic conditions influence cellular ageing and disease susceptibility.

In all three cases, the direction of the effect is consistent with the quiet biology argument: when metabolic conditions are healthy, when NAD⁺ is available, when SIRT1 is active, the regulatory system functions more cleanly. p53 oscillates as it should. The AR is restrained as it should be. Autophagy and mitochondrial quality are maintained. The cell’s own protective machinery is allowed to work.

The protocol does not need to target sirtuins directly because it already supports them through every element it contains. Understanding the sirtuin axis is not primarily an argument for adding another intervention. It is confirmation that the interventions already in place are working through more mechanisms than had been explicitly named, and that the metabolic environment the protocol is restoring is doing more regulatory work than any single molecular pathway can account for.

The cell has more than one way to protect itself.

The question is whether the conditions exist for those protections to function.

References

1. 01Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107(2):149-159. doi:10.1016/S0092-8674(01)00527-X. Also: Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell. 2001;107(2):137-148.
2. 02Fu M, Liu M, Sauve AA, et al. Hormonal control of androgen receptor function through SIRT1. Molecular and Cellular Biology. 2006;26(21):8122-8135. doi:10.1128/MCB.00289-06
3. 03Cantó C, Auwerx J. Caloric restriction, SIRT1 and longevity. Trends in Endocrinology and Metabolism. 2009;20(7):325-331. doi:10.1016/j.tem.2009.03.008
4. 04Guarente L. Calorie restriction and sirtuins revisited. Genes and Development. 2013;27(19):2072-2085. doi:10.1101/gad.227439.113
5. 05Brooks CL, Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein and Cell. 2011;2(6):456-462. doi:10.1007/s13238-011-1063-9. Also: Lee JT, Gu W. SIRT1: regulator of p53 deacetylation. Genes and Cancer. 2013;4(3-4):112-117.
6. 06Huffman DM, Grizzle WE, Bhatt DL, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Research. 2007;67(14):6612-6618. doi:10.1158/0008-5472.CAN-07-0085. Also: Comstock CES, Augello MA, Goodwin JF, et al. Androgen deprivation-induced elevated nuclear SIRT1 promotes prostate tumour cell survival. Cancer Letters. 2021;502:1-11.
7. 07Dai Y, Ngo D, Jacob J, Forman LW, Faller DV. Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Molecular Endocrinology. 2007;21(8):1807-1821. doi:10.1210/me.2006-0467
8. 08Popov VM, Wang C, Shirley LA, et al. The functional significance of nuclear receptor acetylation. Steroids. 2007;72(2):221-230. doi:10.1016/j.steroids.2006.12.001
9. 09Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annual Review of Pathology. 2010;5:253-295. doi:10.1146/annurev.pathol.4.110807.092250